Merck, B8041-.5MG, Biglycan from bovine articular cartilage

General description
proteoglycan consisting of a 45 kDa core protein and two chrondroitin/dermatan sulfate glycosaminoglycan chains
Biochem/physiol Actions
Biglycan interacts with collagen type I and II, fibronectin and TGF-β. In a low ionic strength (less than 3 mM phosphate) buffer, Biglycan binds more strongly to collagen type I. At higher ionic strengths, Biglycan will instead increase the inhibition effect of TGF-β on osteoclast proliferation at a concentration of 4-20 mg/mL. It also functions to prevent the attachment of CHO cells to fibronectin, with a 50% inhibition at 17-21 mg/mL. As an extracellular component, Biglycan binds TGF-β 1, facilitates bone mineralization and supports osteoblast differentiation thru BMP-4 binding.
Preparation Note
This product is extracted from articular cartilage, chematographically purified, dialyzed against water, and 0.2 μm filtered prior to lyophilization. Once lyophilized, this powder is essentially salt-free. The product is soluble in water at 2 mg/mL.
Other Notes
Biglycan is a 200-350 kDa proteoglycan consisting of a 45 kDa core protein and two chondroitin/dermatan sulfate glycosaminoglycan chains.
Disclaimer
Store this product at -20°C. Stored as supplied, this powder shows little decomposition in 3 years when stored properly.